Discover how Ultragenyx achieved 29% revenue growth in 2024, set 2025 guidance at $640M-$670M, and advanced clinical progress toward profitability by 2027.

Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc Howard Horn; ...

Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. At the end of the prepared ...

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its ...

Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million2025 Financial ...

Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...

Ultragenyx Pharmaceutical Inc (RARE) reports a 29% revenue increase in 2024, driven by successful product launches and international expansion, despite a significant net loss.

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

Ultragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...